Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease

Acta Haematologica

Volumn 110, Issue 2-3, 2003, Pages 139-148

  Bollard, Catherine M ^a   Savoldo, Barbara ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Adoptive immunotherapy; Epstein Barr virus; Post transplant lymphoproliferative disease; Transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD21; MONOCLONAL ANTIBODY CD24; OKT 3; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; BIOSAFETY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFUSION; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PATHOGENESIS; PATHOLOGY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TOXICITY; VIRUS INFECTION;

ADOPTIVE TRANSFER; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES; TRANSPLANTS;

EID: 0242299672     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072463     Document Type: Review

References (88)

1. Rickinson AB, Kieff E: Epstein-Barr virus; in Fields BN, Knipe DM, Howley PM (eds): Fields Virology. Philadelphia, Lippincott-Raven, 1996, pp 2397-2446.
2. Rickinson AB: EBV infection and EBV-associated tumors; in Minson AC, Neil JC, McRae MA (eds): Viruses and Cancer. Cambridge, Cambridge University Press, 1994, pp 81-100.
3. Henle G, Henle W, Horwitz C: Antibodies to Epstein-Barr virus-associated antigens in infectious mononucleosis. J Infect Dis 1974;130:231-239.
4. Qu L, Rowe DT: Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 1992;66:3715-3724.
5. Tierney RJ, Steven N, Young LS, Rickinson AB: Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;68:7374-7385.
6. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:405-431.
7. Hopwood P, Crawford DH: The role of EBV in post-transplant malignancies: A review. J Clin Pathol 2000;53:248-254.
8. Lewin N, Aman P, Masucci MG, Klein E, Klein G, Oberg B, Strander H, Henle W, Henle G: Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer 1987;39:472-476.
9. Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson A, Kieff E: Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 1991;88:6343-6347.
10. Brooks L, Yao QY, Rickinson AB, Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA-1 and LMP-2 transcripts. J Virol 1992;66:2689-2697.
11. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS: Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177:339-349.
12. d'Amore ESG, Manivel JC, Gajl-Peczalska KJ, Litz CE, Copenhaver CM, Shapiro RS, Strickler JG: B-cell lymphoproliferations after bone marrow transplant. Cancer 1991;68:1285-1294.
13. Wagner HJ, Bein G, Bitsch A, Kirchner H: Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol 1992;30:2826-2829.
14. Riddler SA, Breinig MC, McKnight JLC: Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-984.
15. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, Todo S, Green M: Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997;35:1612-1615.
16. Orii T, Ohkohchi N, Kikuchi H, Koyamada N, Chubachi S, Satomi S, Kimura H, Hoshino Y, Morita M: Usefulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation. Clin Transplant 2000;14:308-317.
17. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ: Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-2216.
18. Skinner JC, Gilbert EF, Hong R, Bozdech MJ, Flynn B, Borcherding W, Hafez GR, Arya S, Trigg ME, Finlay JL, Sondel PM: B-cell lymphoproliferative disorders following T-cell-depleted allogeneic bone marrow transplantation. Am J Pediatr Hematol Oncol 1988;10:112-119.
19. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH: Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
20. Lucas K, Small T, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996;87:2594-2603.
21. Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ, van den Bergh RL, Waaijer JL, Kroes AC, Kluin PM, Vossen JM: Risk factors for developing EBV-related B cell lymphoproliferative disorders after non-HLA-identical BMT in children. Bone Marrow Transpl 1996;18:377-382.
22. Heslop HE, Rooney CM: Adoptive Immunotherapy of EBV lymphoproliferative diseases. Immunol Rev 1997;157:217-222.
23. Hale G, Waldmann H, for CAMPATH Users: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood 1998;91:3079-3083.
24. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723-1728.
25. Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville D, Reding R, Janssen M, Buts JP, Otte JB: Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997;64:1438-1442.
26. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP: Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-3639.
27. Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, Haskins S, Heerema NA, Ghapure V, Abonour R, Srour EF, Cornetta K: Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997;107:419-429.
28. Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, Bitker MO, Gandjbakhch I, Suberbielle C, Farcet JP: Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994;58:317-324.
29. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I: Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci USA 1988;85:8693-8696.
30. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL: Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985;39:461-472.
31. Swinnen LJ: Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000;11(suppl 1):45-48.
32. Gratama JW, Zutter MM, Minarovits J, Oosterveer MAP, Thomas ED, Klein G, Ernberg I: Expression of Epstein-Barr virus-encoded growth-transformation- associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 1991;47:188-192.
33. Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NKC, Wagner JE, Filipovich AH: B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-258.
34. Claviez A, Tiemann M, Wagner HJ, Dreger P, Suttorp M: Epstein-Barr virus-associated posttransplant lymphoproliferative disease after bone marrow transplantation mimicking graft-versus-host disease. Pediatr Transplant 2000;4:151-155.
35. Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan YJ, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
36. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE: Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995;89:98-103.
37. Stevens SJ, Vervoort MB, van den Brule AJ, Meenhorst PL, Meijer CJ, Middeldorp JM: Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR. J Clin Microbiol 1999;37:2852-2857.
38. Stevens SJ, Verschuuren EA, Pronk I, van der BW, Harmsen MC, The TH, Meijer CJ, van den Brule AJ, Middeldorp JM: Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165-1171.
39. Bollard CM, Rooney CM, Huls MH, Rochester RJ, Benaim E, Krance RA, Brenner MK, Heslop HE: Long-term follow-up of patients who received EBV-specific CTLs for the prevention or treatment of EBV lymphoma (abstract). Blood 2000;96:478.
40. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB: Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989;43:67-71.
41. Swinnen LJ: Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 1999;26(suppl 14):21-25.
42. Fischer A, Blanche S, LeBidois J, Bordigoni P, Garnier JL, Neaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C, Hirn M: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-1456.
43. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A: Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
44. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE: CD20 monoclonal antibody (Rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-1505.
45. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR: Treatment of posttransplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant 2001;27:329-332.
46. Schaar CG, van der Pijl JW, van Hoek B, de Fijter JW, Veenendaal RA, Kluin PM, Van Krieken JH, Hekman A, Terpstra WE, Willemze R, Kluin-Nelemans HC: Successful outcome with a 'quintuple approach' of posttransplant lymphoproliferative disorder. Transplantation 2001;71:47-52.
47. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM: CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with Rituximab. Am J Hematol 2000;65:171-173.
48. Papadopoulos EB, Ladanyi M, Emanuel D, MacKinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
49. Heslop HE, Brenner MK, Rooney CM: Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-680.
50. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995;345:9-13.
51. Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M: Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 2001;27:53-64.
52. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L: Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997;157:195-216.
53. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807-814.
54. Bollard C, Onishi H, Huls M, Rochester R, Benaim E, Krance R, Brenner M, Rooney C, Heslop H: Long-term follow-up of patients who received EBV-specific CTLs for the prevention or treatment of EBV-associated lymphoproliferative disease (abstract). Biol Blood Marrow Transplant 2001;7:61.
55. Gottschalk S, Ng CYC, Smith CA, Perez M, Sample C, Brenner MK, Heslop HE, Rooney CM: An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T-cell therapy. Blood 2001;97:835-843.
56. Cohen JI: Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991;70:137-160.
57. Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE: Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999;68:1851-1854.
58. Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE: Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996;119:544-551.
59. Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA, Griffith BP, Fricker FJ: Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997;131:309-313.
60. Todo S, Tzakis A, Reyes J, Abu-Elmagd K, Furukawa H, Fung K, Starzl TE: Intestinal transplantation: 4-year experience. Transplant Proc 1995;27:1355-1356.
61. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME: The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000;70:94-99.
62. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A: Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-968.
63. Emanuel DJ, Lucas KG, Mallory GB, Edwards-Brown MK, Pollok KE, Conrad PD, Robertson KA, Smith FO: Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leucocytes. Transplantation 1997;63:1691-1694.
64. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998;16:2052-2059.
65. Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B, Borleri G, Manzoni C, Viero P, Remuzzi G, Barbui T, Rambaldi A: Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-833.
66. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH: Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000;24:375-385.
67. Starzl TE, Naleskin MA, Porter KA, Ho M, Iwatsaki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchinson RW, Jaffe R, Behnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;i:583.
68. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR Jr: Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996;62:370-375.
69. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI: Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-852.
70. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC: Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998;66:1770-1779.
71. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD: Treatment of post-transplant lymphoproliferative disease with Rituximab monoclonal antibody after lung transplantation. Lancet 1999;354:1698-1699.
72. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, de Ligny BH, Dubief F, Mathieu-Boue A, Leblond V: Humanized anti-CD20 monoclonal antibody (Rituximab) in posttransplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11(suppl 1):113-116.
73. Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, Gridelli B, Barbui T: Anti-CD20 antibody (Rituximab) administration in patients with late-occurring lymphomas after solid organ transplant. Haematologica 2001;86:618-623.
74. Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-615.
75. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
76. Gross TG, Hinrichs SH, Winner J, Greiner TC, Kaufman SS, Sammut PH, Langnas AN: Treatment of post-transplant lymphoproliferative disease following solid organ transplantation with low-dose chemotherapy. Ann Oncol 1998;9:339-340.
77. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-565.
78. Razzouk BI, Srinivas S, Sample CE, Singh V, Sixbey JW: Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996;173:529-535.
79. Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML: Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999;68:997-1003.
80. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I: Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995;103:748-755.
81. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Grittsch HA, Elder E, Whiteside TL, Starzl TE: Autologous lymphokine-activated killer cell therapy of Ep-stein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1998;63:1200-1205.
82. Haque T, Crawford DH: The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Br J Haematol 1999;106:309-316.
83. Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K, Burroughs AK, Prentice HG, Crawford DH: Reconstitution of EBV-specific T-cell immunity in solid organ transplant recipients. J Immunol 1998;160:6204-6209.
84. Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL, Moss DJ: Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96:10391-10396.
85. Savoldo B, Goss J, Liu Z, Huls H, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM: Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2003;72:1078-1086.
86. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C: Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-2722.
87. Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, Reyes J: Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998;66:1641-1644.
88. Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, Maccario R, Fiocchi R, Gerna G: High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000;38:613-619.